REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot116410.21518/1561-5936-2019-11-62-69Original ArticleInvestment activity and financial results of pharmaceutical companies: intermediate results of 2019RomanovaSvetlananoemail@neicon.ru1112201911626918032022Copyright © 2019,2019The analysis of investment activity of pharmaceutical industry enterprises was carried out according to the data of the state statistical reporting form No. P-2 «Information on Investments in Non-Financial Assets». Investments in fixed capital of enterprises in various sectors of the economy by type of activity with the OKVED221 code: «Production of medicines and materials used for medical purposes» in the first half of 2019 in Russia amounted to 18.609 billion rubles, which is 1.84 times higher than the previous year. In the first half of 2019, pharmaceutical companies with the OKVED221 code invested 18.595 billion rubles in fixed assets. The source of these investments was mainly own funds of the industry enterprises - 15.476 billion rubles, or 83.23% of the total amount. The main source of funds raised was bank loans - 1.922 billion rubles, or 61.62%, as well as borrowings from other organizations - 0.505 billion rubles, or 16.19% of the total amount of funds raised. It is possible to assess the financial condition of the industry enterprises by the level of financial stability and solvency, which are characterized by appropriate coefficients. Let's consider in general for the industry the values of the coefficients that characterize: a) financial stability: the ratio of borrowed and own funds, the coefficient of autonomy, the coefficient of maneuverability and the coefficient of own funds availability, b) solvency: the coefficient of absolute liquidity, the liquidity ratio and the coverage ratio. As the results of the analysis of the financial condition of pharmaceutical industry enterprises have shown, all the coefficients that characterize the level of financial stability and solvency of the industry enterprises were within the normative values. The only exception was the absolute liquidity and coverage coefficients, which turned out to be lower than the normative level.medical industrypharmaceutical industrymedicinesenterprisesanalysisinvestmentsfixed assetsown fundsraised fundsfinancial resultsfinancial conditionмедицинская промышленностьфармацевтическая промышленностьлекарственные средствапредприятияанализинвестицииосновной капиталсобственные средствапривлеченные средствафинансовые результатыфинансовое состояние1.Романова С.А. Ежемесячный обзор: Производство, инвестиции, финансы. Ремедиум. 2018;(11):64-69. doi: 10.21518/1561-5936-2018-11-6469. Romanova S.A. Monthly review: production, investment, finance. Remedium. 2018;(11):64-69. (In Russ.) doi: 10.21518/1561-5936-2018-11-64-69.2.Романова С.А. Ежемесячный обзор: Производство, инвестиции, финансы. Ремедиум. 2018;(12):60-70. doi: 10.21518/1561-5936-2018-12-6070. Romanova S.A. Monthly review: production, investment, finance. Remedium. 2018;(12):60-70. (In Russ.) doi: 10.21518/1561-5936-2018-12-60-70.3.Захарова В.М., Романова С.А. Инвестиции в развитие медицинской промышленности. Лучше мало, чем ничего. Ремедиум. 2000;(10):20-27. Захарова В.М., Романова С.А. Инвестиции в развитие медицинской промышленности. Лучше мало, чем ничего. Ремедиум. 2000;(10):20-27. (In Russ.)4.Крейнина М.Н. Анализ финансового состояния и инвестиционной привлекательности акционерных обществ в промышленности, строительстве и торговле. М., 1994.